The DOI matches its Crossref record; 142 of the 143 references it cites were found in a registry or an index.
Body Fluid Cytokine Levels in Mild Cognitive Impairment and Alzheimer’s Disease: a Comparative Overview
Open accessAbstract
This article gives a comprehensive overview of cytokine and other inflammation associated protein levels in plasma, serum and cerebrospinal fluid (CSF) of patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI). We reviewed 118 research articles published between 1989 and 2013 to compare the reported levels of 66 cytokines and other proteins related to regulation and signaling in inflammation in the blood or CSF obtained from MCI and AD patients. Several cytokines are evidently regulated in (neuro-) inflammatory processes associated with neurodegenerative disorders. Others do not display changes in the blood or CSF during disease progression. However, many reports on cytokine levels in MCI or AD are controversial or inconclusive, particularly those which provide data on frequently investigated cytokines like tumor necrosis factor alpha (TNF-α) or interleukin-6 (IL-6). The levels of several cytokines are possible indicators of neuroinflammation in AD. Some of them might increase steadily during disease progression or temporarily at the time of MCI to AD conversion. Furthermore, elevated body fluid cytokine levels may correlate with an increased risk of conversion from MCI to AD. Yet, research results are conflicting. To overcome interindividual variances and to obtain a more definite description of cytokine regulation and function in neurodegeneration, a high degree of methodical standardization and patients collective characterization, together with longitudinal sampling over years is essential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Hypothetical time course of CSF cytokine expression in AD. Graphs display the estimated CSF concentration changes of amyloid and tau protein during the development of AD, as described by others [142]. As different cytokines and other inflammatory proteins appear to display different changes in CSF levels during disease development, they might be divided into groups: First, cytokines like IL-1α or IL-2 which might remain unchanged in AD; Second, cytokines like IL-1β, IL-6 or TNF-α which might increase slowly during disease progression; third, cytokines like IL-18, MCP-1 or IP-10 which might show a peak at certain disease stages, especially at time of MCI to AD conversion. However, data becomes scarce for early disease stages. To test this hypothesis and the grouping of cytokines, longitudinal CSF sampling from individuals at risk of dementia over years would be the most efficient way](https://figures.cochat.ai/paper-figures/7bf10579d0cf4f008c0f6efa1c223a78/body-fluid-cytokine-levels-in-mild-cognitive-impairment-and-alzheimers-disease-a-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many inflammatory mediators known to increase with aging (IL-1β, IL-18, sTNF-R1) are upregulated to an even greater extent in neurodegenerative conditions such as AD and Parkinson’s disease (PD) (100, 145–147).”
From Connecting aging biology and inflammation in the omics era (2022) · cites this paper as [145]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Neuroinflammation is a key contributor to AD progression. While early immune responses may aid in the clearance of Aβ and tau aggregates, prolonged activation of microglia and astrocytes leads to chronic inflammation and the release of pro-inflammatory cytokines such as IL-1β and TNF-α, promoting neuronal damage in vulnerable brain regions like the neocortex and hippocampus [34–36].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Levels of these pro-inflammatory cytokines (including IL-1β, IL-6, IL-8, IL-18 and TNF) are upregulated in serum, cerebrospinal fluid (CSF) and post-mortem brain tissue of AD patients [23–25].”
From Microglial function, INPP5D/SHIP1 signaling, and NLRP3 inflammasome activation: implications for Alzheimer’s disease (2023) · cites this paper as [25]
Experimental — accuracy not yet measuredIn the citing paper
“In vivo imaging shows that microglia activation precedes the onset of AD (100) and is paralleled by increased levels of inflammatory markers in the cerebrospinal fluid (101)”
From Microglia in Alzheimer's disease (2017) · cites this paper as [101]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Chronic stress and age-related increases in the proinflammatory cytokine IL-6.
Kiecolt-Glaser, J. K., Preacher, K. J., MacCallum, R. C., Atkinson, C., Malarkey, W. B., & Glaser, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1531903100 · Cited by 1,267 · cited 1×
“Additionally, systemic levels of cytokines may rise in response to aging and stress, known risk factors for neurodegeneration [6–8].”
BackgroundSystemic inflammation and disease progression in Alzheimer disease
Holmes, C., Cunningham, C., Zotova, E., Woolford, J., Dean, C., Kerr, S., Culliford, D., & Perry, V. H. (2009) · Neurology · doi:10.1212/wnl.0b013e3181b6bb95 · Cited by 1,139 · cited 1×
“Other studies outlined correlations between cytokine levels and disease risk, progression or MCI to AD conversion [27, 29–48].”
BackgroundA Meta-Analysis of Cytokines in Alzheimer's Disease
Swardfager, W., Lanctôt, K., Rothenburg, L., Wong, A., Cappell, J., & Herrmann, N. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.06.012 · Cited by 1,108
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048
Historical insights into cytokines
Dinarello, C. A. (2007) · European Journal of Immunology · doi:10.1002/eji.200737772 · Cited by 926
Blum-Degena, D., Müller, T., Kuhn, W., Gerlach, M., Przuntek, H., & Riederer, P. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)12192-7 · Cited by 801
The role of inflammation in Alzheimer’s disease
Tuppo, E. E., & Arias, H. R. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2004.07.009 · Cited by 734
Early inflammation and dementia: A 25‐year follow‐up of the Honolulu‐Asia aging study
Schmidt, R., Schmidt, H., Curb, J. D., Masaki, K., White, L. R., & Launer, L. J. (2002) · Annals of Neurology · doi:10.1002/ana.10265 · Cited by 710
Inflammatory markers and cognition in well-functioning African-American and white elders
Yaffe, K., Lindquist, K., Penninx, B. W., Simonsick, E. M., Pahor, M., Kritchevsky, S., Launer, L., Kuller, L., Rubin, S., & Harris, T. (2003) · Neurology · doi:10.1212/01.wnl.0000073620.42047.d7 · Cited by 706
Interleukin-6 and risk of cognitive decline: MacArthur Studies of Successful Aging
Weaver, J. D., Huang, M.-H., Albert, M., Harris, T., Rowe, J. W., & Seeman, T. E. (2002) · Neurology · doi:10.1212/wnl.59.3.371 · Cited by 536
Elevated circulating tumor necrosis factor levels in Alzheimer's disease
Fillit, H., Ding, W., Buee, L., Kalman, J., Altstiel, L., Lawlor, B., & Wolf-Klein, G. (1991) · Neuroscience Letters · doi:10.1016/0304-3940(91)90490-k · Cited by 512
Intrathecal inflammation precedes development of Alzheimer's disease
Tarkowski, E. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.9.1200 · Cited by 501 · cited 2×
“or serum, whereas one study reports downregulation in CSF [3, 19, 32, 51, 52, 63].”
BackgroundA High Plasma Concentration of TNF- Is Associated With Dementia in Centenarians
Bruunsgaard, H., Andersen-Ranberg, K., Jeune, B., Pedersen, A. N., Skinhoj, P., & Pedersen, B. K. (1999) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/54.7.m357 · Cited by 459
Inflammatory markers and the risk of Alzheimer disease: The Framingham Study
Tan, Z. S., Beiser, A. S., Vasan, R. S., Roubenoff, R., Dinarello, C. A., Harris, T. B., Benjamin, E. J., Au, R., Kiel, D. P., Wolf, P. A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000263217.36439.da · Cited by 440
Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease
Doecke, J. D. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1282 · Cited by 421
Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease–like pathology and cognitive decline
vom Berg, J., Prokop, S., Miller, K. R., Obst, J., Kälin, R. E., Lopategui-Cabezas, I., Wegner, A., Mair, F., Schipke, C. G., Peters, O., et al. (2012) · Nature Medicine · doi:10.1038/nm.2965 · Cited by 416
Licastro, F., Pedrini, S., Caputo, L., Annoni, G., Davis, L. J., Ferri, C., Casadei, V., & Grimaldi, L. M. E. (2000) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00226-x · Cited by 400
The Association Between Delirium and Cognitive Decline: A Review of the Empirical Literature
Jackson, J. C., Gordon, S. M., Hart, R. P., Hopkins, R. O., & Ely, E. W. (2004) · Neuropsychology Review · doi:10.1023/b:nerv.0000028080.39602.17 · Cited by 388
Tarkowski, E., Issa, R., Sjögren, M., Wallin, A., Blennow, K., Tarkowski, A., & Kumar, P. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00285-8 · Cited by 360
Tarkowski, E., Blennow, K., Wallin, A., & Tarkowski, A. (1999) · Journal of Clinical Immunology · doi:10.1023/a:1020568013953 · Cited by 349
Serum inflammatory proteins and cognitive decline in older persons
Dik, M. G., Jonker, C., Hack, C. E., Smit, J. H., Comijs, H. C., & Eikelenboom, P. (2005) · Neurology · doi:10.1212/01.wnl.0000158281.08946.68 · Cited by 339
Elevated levels of tumor necrosis factor alpha and mortality in centenarians
Bruunsgaard, H., Andersen-Ranberg, K., Hjelmborg, J. V. B., Pedersen, B. K., & Jeune, B. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(03)00329-2 · Cited by 325
Stage-dependent BDNF serum concentrations in Alzheimer’s disease
Laske, C., Stransky, E., Leyhe, T., Eschweiler, G. W., Wittorf, A., Richartz, E., Bartels, M., Buchkremer, G., & Schott, K. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-005-0397-y · Cited by 324
The Role of Peripheral Inflammatory Markers in Dementia and Alzheimer's Disease: A Meta-Analysis
Koyama, A., O'Brien, J., Weuve, J., Blacker, D., Metti, A. L., & Yaffe, K. (2013) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/gls187 · Cited by 322
Intrathecal Chemokine Synthesis in Mild Cognitive Impairment and Alzheimer Disease
Galimberti, D., Schoonenboom, N., Scheltens, P., Fenoglio, C., Bouwman, F., Venturelli, E., Guidi, I., Blankenstein, M. A., Bresolin, N., & Scarpini, E. (2006) · Archives of Neurology · doi:10.1001/archneur.63.4.538 · Cited by 289
Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease
Álvarez, A., Cacabelos, R., Sanpedro, C., García-Fantini, M., & Aleixandre, M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.012 · Cited by 278
Contribution of systemic inflammation to chronic neurodegeneration
Perry, V. H. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0722-x · Cited by 277
Westin, K., Buchhave, P., Nielsen, H., Minthon, L., Janciauskiene, S., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030525 · Cited by 277
Laske, C., Stransky, E., Leyhe, T., Eschweiler, G. W., Maetzler, W., Wittorf, A., Soekadar, S., Richartz, E., Koehler, N., Bartels, M., et al. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.01.014 · Cited by 272 · cited 1×
“The effects reported for BDNF were mostly modest whereas interindividual differences were high and overlapping between the groups [35–37, 78, 136–139].”
BackgroundNeuroinflammation and Synaptic Loss
Rao, J. S., Kellom, M., Kim, H.-W., Rapoport, S. I., & Reese, E. A. (2012) · Neurochemical Research · doi:10.1007/s11064-012-0708-2 · Cited by 261
Neuroinflammation – An Early Event in Both the History and Pathogenesis of Alzheimer’s Disease
Eikelenboom, P., van Exel, E., Hoozemans, J. J. M., Veerhuis, R., Rozemuller, A. J. M., & van Gool, W. A. (2010) · Neurodegenerative Diseases · doi:10.1159/000283480 · Cited by 259
Craig-Schapiro, R., Kuhn, M., Xiong, C., Pickering, E. H., Liu, J., Misko, T. P., Perrin, R. J., Bales, K. R., Soares, H., Fagan, A. M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018850 · Cited by 237
Expression of interleukin-18 is increased in the brains of Alzheimer’s disease patients
Ojala, J., Alafuzoff, I., Herukka, S.-K., van Groen, T., Tanila, H., & Pirttilä, T. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.06.006 · Cited by 235
Increased Serum IL-1β Level in Alzheimer’s Disease and Mild Cognitive Impairment
Forlenza, O. V., Diniz, B. S., Talib, L. L., Mendonça, V. A., Ojopi, E. B., Gattaz, W. F., & Teixeira, A. L. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000255051 · Cited by 219
Cerebral pattern of pro- and anti-inflammatory cytokines in dementias
Tarkowski, E., Liljeroth, A.-M., Minthon, L., Tarkowski, A., Wallin, A., & Blennow, K. (2003) · Brain Research Bulletin · doi:10.1016/s0361-9230(03)00088-1 · Cited by 219
Plasma Biomarkers Associated With the Apolipoprotein E Genotype and Alzheimer Disease
Soares, H. D. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1070 · Cited by 218
Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer’s disease
Galimberti, D., Fenoglio, C., Lovati, C., Venturelli, E., Guidi, I., Corrà, B., Scalabrini, D., Clerici, F., Mariani, C., Bresolin, N., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.10.007 · Cited by 209
Angelucci, F., Spalletta, G., Iulio, F., Ciaramella, A., Salani, F., Varsi, A., Gianni, W., Sancesario, G., Caltagirone, C., & Bossu, P. (2010) · Current Alzheimer Research · doi:10.2174/156720510790274473 · Cited by 186
Higher BDNF serum levels predict slower cognitive decline in Alzheimer's disease patients
Laske, C., Stellos, K., Hoffmann, N., Stransky, E., Straten, G., Eschweiler, G. W., & Leyhe, T. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001008 · Cited by 180
Bermejo, P., Martín-Aragón, S., Benedí, J., Susín, C., Felici, E., Gil, P., Ribera, J. M., & Villar, Á. M. (2008) · Immunology Letters · doi:10.1016/j.imlet.2008.02.002 · Cited by 178
Lanzrein, A.-S., Johnston, C. M., Perry, V. H., Jobst, K. A., King, E. M., & Smith, A. D. (1998) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199809000-00016 · Cited by 178
Yasutake, C., Kuroda, K., Yanagawa, T., Okamura, T., & Yoneda, H. (2006) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-006-0652-8 · Cited by 177
Altered plasma cytokine levels in Alzheimer's disease: Correlation with the disease progression
Motta, M., Imbesi, R., Di Rosa, M., Stivala, F., & Malaguarnera, L. (2007) · Immunology Letters · doi:10.1016/j.imlet.2007.09.002 · Cited by 176
Zuliani, G., Cavalieri, M., Galvani, M., Passaro, A., Munari, M. R., Bosi, C., Zurlo, A., & Fellin, R. (2008) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2008.05.020 · Cited by 173
Blasko, I., Lederer, W., Oberbauer, H., Walch, T., Kemmler, G., Hinterhuber, H., Marksteiner, J., & Humpel, C. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000089137 · Cited by 170
Li, G., Peskind, E. R., Millard, S. P., Chi, P., Sokal, I., Yu, C., Bekris, L. M., Raskind, M. A., Galasko, D. R., & Montine, T. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005424 · Cited by 167
Kálmán, J., Juhász, A., Laird, G., Dickens, P., Járdánházy, T., Rimanóczy, A., Boncz, I., Parry-Jones, W. L. I., & Janka, Z. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1997.tb00275.x · Cited by 167
Circulating cytokines in Alzheimer's disease
Singh, V. K., & Guthikonda, P. (1997) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(97)00023-x · Cited by 163
Systemic immune aberrations in Alzheimer's disease patients
Bonotis, K. S., Krikki, E., Holeva, V., Aggouridaki, C., Costa, V., & Balogiannis, S. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2007.10.020 · Cited by 147
Licastro, F., Masliah, E., Pedrini, S., & Thal, L. J. (2000) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000017209 · Cited by 144
Marksteiner, J., Kemmler, G., Weiss, E. M., Knaus, G., Ullrich, C., Mechtcheriakov, S., OBERBAUER, H., Auffinger, S., Hinterhoelzl, J., Hinterhuber, H., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.03.011 · Cited by 143
Buchhave, P., Zetterberg, H., Blennow, K., Minthon, L., Janciauskiene, S. M., & Hansson, O. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.10.012 · Cited by 140
Peripheral Cytokines and Chemokines in Alzheimer’s Disease
Lee, K. S., Chung, J. H., Choi, T.-K., Suh, S. Y., Oh, B. H., & Hong, C. H. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000245156 · Cited by 140
Blood levels of histamine, IL-1β, and TNF-α in patients with mild to moderate alzheimer disease
Alvarez, X. A., Franco, A., Fernández-Novoa, L., & Cacabelos, R. (1996) · Molecular and Chemical Neuropathology · doi:10.1007/bf02815005 · Cited by 139
Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease
Björkqvist, M., Ohlsson, M., Minthon, L., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029868 · Cited by 135
Cerebrospinal Fluid Markers in Dementia With Lewy Bodies Compared With Alzheimer Disease
Gómez‐Tortosa, E., Gonzalo, I., Fanjul, S., Sainz, M. J., Cantarero, S., Cemillán, C. A., de Yébenes, J. G., & del Ser, T. (2003) · Archives of Neurology · doi:10.1001/archneur.60.9.1218 · Cited by 135
Burnham, S. C., Faux, N. G., Wilson, W. J., Laws, S. M., Ames, D. J., Bedő, J., Bush, A. I., Doecke, J. D., Ellis, K. A., Head, R. J., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.40 · Cited by 125
Increased intrathecal TGF-β1, but not IL-12, IFN-γ and IL-10 levels in Alzheimer’s disease patients
Rota, E., Bellone, G., Rocca, P., Bergamasco, B., Emanuelli, G., & Ferrero, P. (2006) · Neurological Sciences · doi:10.1007/s10072-006-0562-6 · Cited by 125
Increase in Circulating Levels of Monocyte Chemoattractant Protein-1 with Aging
Inadera, H., Egashira, K., Takemoto, M., Ouchi, Y., & Matsushima, K. (1999) · Journal of Interferon & Cytokine Research · doi:10.1089/107999099313127 · Cited by 122
Soares, H. D., Chen, Y., Sabbagh, M. N., Rohrer, A., Schrijvers, E. M. C., & Breteler, M. M. B. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05066.x · Cited by 121
Chemokines in serum and cerebrospinal fluid of Alzheimer's disease patients
Galimberti, D., Schoonenboom, N. S. M., Scarpini, E. A., & Scheltens, P. (2003) · Annals of Neurology · doi:10.1002/ana.10531 · Cited by 116
Study of interleukin-6 production in Alzheimer's disease.
Cojocaru, I. M., Cojocaru, M., Miu, G., & Sapira, V. (2011) · PubMed · Cited by 114
Increased cerebrospinal fluid levels of transforming growth factor-β1 in Alzheimer’s disease
Zetterberg, H., Andreasen, N., & Blennow, K. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.06.001 · Cited by 111
Solerte, S. B., Cravello, L., Ferrari, E., & Fioravanti, M. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb05399.x · Cited by 109
Maes, M. H. J., Devos, N., Wauters, A., Demedts, P., Maurits, V., Neels, H. M., Bosmans, E., Altamura, C. A., Lin, A., Song, C., et al. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00016-3 · Cited by 108
Higher Serum sTNFR1 Level Predicts Conversion from Mild Cognitive Impairment to Alzheimer's Disease
Diniz, B. S., Teixeira, A. L., Ojopi, E. P. B., Talib, L. L., Mendonça, V. A., Gattaz, W. F., & Forlenza, O. V. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100921 · Cited by 108
Decline of immune responsiveness: A pathogenetic factor in Alzheimer’s disease?
Richartz, E., Stransky, E., Batra, A., Simon, P. D., Lewczuk, P., Buchkremer, G., BARTELS, M., & Schott, K. J. (2005) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2004.12.005 · Cited by 108
Brain-Derived Neurotrophic Factor Levels in Alzheimer's Disease
O’Bryant, S. E., Hobson, V. L., Hall, J. R., Waring, S. C., Chan, W., Massman, P. J., Lacritz, L. H., Cullum, C. M., & Diaz-Arrastia, R. R. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1051 · Cited by 104
Jia, J., Meng, R., Sun, Y., Sun, W., Ji, X., & Jia, L. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.03.051 · Cited by 104
Cytokines in Alzheimer's Disease and Vascular Dementia
Angelopoulos, P., Aggouridaki, H., Vaiopoulos, H., Siskou, E., Doutsou, K., Costa, V., & Balogiannis, S. (2008) · International Journal of Neuroscience · doi:10.1080/00207450701392068 · Cited by 102
Transforming growth factor beta in Alzheimer's disease
Chao, C. C., Hu, S., Frey, W. H., A, T., Tourtellotte, W. W., & Peterson, P. K. (1994) · Clinical and Diagnostic Laboratory Immunology · doi:10.1128/cdli.1.1.109-110.1994 · Cited by 102
Locascio, J. J., Fukumoto, H., Yap, L., Bottiglieri, T., Growdon, J. H., Hyman, B. T., & Irizarry, M. C. (2008) · Archives of Neurology · doi:10.1001/archneur.65.6.776 · Cited by 101
DeKosky, S. T., Ikonomović, M. D., Wang, X., Farlow, M. R., Wisniewski, S. R., López, O. L., Becker, J. T., Saxton, J. A., Klunk, W. E., Sweet, R. A., et al. (2002) · Annals of Neurology · doi:10.1002/ana.10414 · Cited by 98
Combination of serum markers related to several mechanisms in Alzheimer’s disease
Teunissen, C. E., Lütjohann, D., von Bergmann, K., Verhey, F. R. J., Vreeling, F. W., Wauters, A., Bosmans, E., Bosma, H., van Boxtel, M. P. J., Maes, M. H. J., et al. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00005-8 · Cited by 97
Hampel, H. J., Teipel, S. J., Padberg, F., Haslinger, A., Riemenschneider, M., Schwarz, M., Kötter, H. U., Scheloske, M., Buch, K., Stübner, S., et al. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01146-4 · Cited by 96
Galimberti, D., Venturelli, E., Fenoglio, C., Guidi, I., Villa, C., Bergamaschini, L. C., Cortini, F., Scalabrini, D., Baron, P., Vergani, C., et al. (2008) · Journal of Neurology · doi:10.1007/s00415-008-0737-6 · Cited by 95
α1-Antichymotrypsin and IL-1β are not increased in CSF or serum in Alzheimer's disease
Pirttilä, T., Mehta, P. D., Frey, H., & Wísniewski, H. M. (1994) · Neurobiology of Aging · doi:10.1016/0197-4580(94)90026-4 · Cited by 94
Malaguarnera, L., Motta, M., Di Rosa, M., Anzaldi, M., & Malaguarnera, M. (2006) · Neuropathology · doi:10.1111/j.1440-1789.2006.00701.x · Cited by 93
Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease
Angelis-Stoforidis, P., Scharf, S., Mander, A. G., Vajda, F. J. E., & Christophidis, N. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00136-0 · Cited by 88
Johnstone, D. M., Milward, E. A., Berretta, R. E., Moscato, P., & Initiative, A. D. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034341 · Cited by 88
Martins, T. B. (2002) · Clinical and Vaccine Immunology · doi:10.1128/cdli.9.1.41-45.2002 · Cited by 88
Garlind, A., Brauner, A., Höjeberg, B., Basun, H., & Schultzberg, M. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01092-6 · Cited by 87
Inflammatory markers in Alzheimer's disease and multi-infarct dementia
Luigi, A. D., Fragiacomo, C., Lucca, U., Quadri, P., Tettamanti, M., & Simoni, M. G. D. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(01)00313-x · Cited by 86
Serum cytokine levels in patients with Alzheimer's disease
Chao, C. C., A, T., Hu, S., Crossley, K., Sherman, R. E., Peterson, P. K., & Frey, W. H. (1994) · Clinical and Diagnostic Laboratory Immunology · doi:10.1128/cdli.1.4.433-436.1994 · Cited by 85
Increased cerebrospinal fluid Fas (Apo-1) levels in Alzheimer’s disease
Martínez, M., Fernández-Vivancos, E., Frank, A., la Fuente, M. D., & Hernánz, Á. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02363-5 · Cited by 84
Chemokines in CSF of Alzheimer's disease patients
Corrêa, J. D., Starling, D. S. V., Teixeira, A. L., Caramelli, P., & Silva, T. A. (2011) · Arquivos de Neuro-Psiquiatria · doi:10.1590/s0004-282x2011000400009 · Cited by 84
Licastro, F., Parnetti, L., Morini, M. C., Davis, L. J., Cucinotta, D., GAITI, A., & Senin, U. (1995) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199509020-00009 · Cited by 84
Serum levels of interleukin-6 are not elevated in patients with Alzheimer's disease
van Duijn, C. M., Albert Hofman, D., & Nagelkerken, L. M. (1990) · Neuroscience Letters · doi:10.1016/0304-3940(90)90666-w · Cited by 80
Mocali, A., Cedrola, S., Malva, N. D., Bontempelli, M., Costanza, V. A. M., Bavazzano, A., Comolli, R., Paoletti, F., & Porta, C. A. M. L. (2004) · Experimental Gerontology · doi:10.1016/j.exger.2004.07.007 · Cited by 79
Increased Soluble Tumor Necrosis Factor Receptor Levels in the Serum of Elderly People
Hasegawa, Y., Sawada, M., Ozaki, N., Inagaki, T., & Suzumura, A. (2000) · Gerontology · doi:10.1159/000022157 · Cited by 79
März, P., Heese, K., Höck, C., Golombowski, S., Müller-Spahn, F., Rose‐John, S., & Otten, U. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00886-0 · Cited by 74
O’Bryant, S. E., Hobson, V. L., Hall, J. R., Barber, R. C., Zhang, S., Johnson, L. A., & Diaz-Arrastia, R. R. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000321980 · Cited by 73
Choi, C., Jeong, J.-H., Jang, J. S., Choi, K., Lee, J., Kwon, J., Choi, K., Lee, J.-S., & Kang, S. W. (2008) · Journal of Clinical Neurology · doi:10.3988/jcn.2008.4.2.84 · Cited by 73
Identification of peripheral inflammatory markers between normal control and Alzheimer's disease
Kim, S.-M., Song, J., Kim, S., Han, C., Park, M. H., Koh, Y., Jo, S. A., & Kim, Y.-Y. (2011) · BMC Neurology · doi:10.1186/1471-2377-11-51 · Cited by 70
Engelborghs, S., Brabander, M. D., Crée, J. D., D’Hooge, R., Geerts, H., Verhaegen, H., & Deyn, P. P. D. (1999) · Neurochemistry International · doi:10.1016/s0197-0186(99)00031-5 · Cited by 69
Decreased interleukin-6 level in the cerebrospinal fluid of patients with Alzheimer-type dementia
Yamada, K., Kono, K., Umegaki, H., Yamada, K., Iguchi, A., Fukatsu, T., Nakashima, N., Nishiwaki, H., Shimada, Y., Sugita, Y., et al. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11318-q · Cited by 69
Serum tumor necrosis factor (TNF) in Alzheimer's disease and multi-infarct dementia.
Cacabelos, R., Alvarez, X. A., Franco-Maside, A., Fernández‐Novoa, L., & Caamaño, J. C. (1994) · PubMed · Cited by 69
Serum α1-antichymotrypsin level as a marker for Alzheimer-type dementia
Lieberman, J., Schleissner, L. A., Tachiki, K. H., & Kling, A. S. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)00056-k · Cited by 64
Zuliani, G., Guerra, G., Ranzini, M., Rossi, L., Munari, M. R., Zurlo, A., Blè, A., Volpato, S., Atti, A. R., & Fellin, R. (2006) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1674 · Cited by 63
Bonaccorso, S., Lin, A., Song, C., Verkerk, R. M., Kenis, G., Bosmans, E., Scharpé, S., Vandewoude, M. F. J., Dossche, A., & Maes, M. H. J. (1998) · Aging Clinical and Experimental Research · doi:10.1007/bf03339794 · Cited by 62
Effects of Aging on Inflammation and Hemostasis through the Continuum of Critical Illness.
Kale, S. S., & Yende, S. P. (2011) · Europe PMC (PubMed Central) · Cited by 61
Relationship between Inflammatory Mediators, A? Levels and ApoE Genotype in Alzheimer Disease
Reale, M., Kamal, M. A., Velluto, L., Gambi, D., Nicola, M. D., & Greig, N. H. (2012) · Current Alzheimer Research · doi:10.2174/156720512800492549 · Cited by 61
Hampel, H. J., Schoen, D., Schwarz, M., Kötter, H. U., Schneider, C., Sunderland, T., Dukoff, R. A., Levy, J., Padberg, F., Stübner, S., et al. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00379-0 · Cited by 59
Peripheral Inflammatory Response in Alzheimer's Disease and Multiinfarct Dementia
Luigi, A. D., Pizzimenti, S., Quadri, P., Lucca, U., Tettamanti, M., Fragiacomo, C., & Simoni, M. G. D. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0556 · Cited by 59
Ringman, J. M., Elashoff, D. A., Geschwind, D. H., Welsh, B. T., Gylys, K. H., Lee, C., Cummings, J. L., & Cole, G. M. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.277 · Cited by 58
Licastro, F., Morini, M. C., Polazzi, E., & Davis, L. J. (1995) · Journal of Neuroimmunology · doi:10.1016/0165-5728(94)00163-i · Cited by 58
Inflammation and clinical presentation in neurodegenerative disease: a volatile relationship
Bettcher, B. M., & Kramer, J. H. (2012) · Neurocase · doi:10.1080/13554794.2011.654227 · Cited by 58
Lindberg, C., Chromek, M., Ahrengart, L., Brauner, A., Schultzberg, M., & Garlind, A. (2005) · Neurochemistry International · doi:10.1016/j.neuint.2005.01.004 · Cited by 58
Murase, K., Nabeshima, T., Robitaille, Y., Quirion, R., Ogawa, M., & Hayashi, K. (1993) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1993.1609 · Cited by 57
Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease
Hampel, H. J., Sunderland, T., Kötter, H. U., Schneider, C., Teipel, S. J., Padberg, F., Dukoff, R. A., Levy, J., & Möller, H. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01355-3 · Cited by 57
Bioplex analysis of plasma cytokines in Alzheimer’s disease and mild cognitive impairment
Lee, K. S., Chung, J. H., Lee, K. H., Shin, M., Oh, B. H., & Hong, C. H. (2008) · Immunology Letters · doi:10.1016/j.imlet.2008.09.004 · Cited by 53
Servi, B. D., Porta, C. A. M. L., Bontempelli, M., & Comolli, R. (2002) · Experimental Gerontology · doi:10.1016/s0531-5565(02)00018-9 · Cited by 53
The Mast Syndrome: A Recessively Inherited Form of Presenile Dementia With Motor Disturbances
Cross, H. E. (1967) · Archives of Neurology · doi:10.1001/archneur.1967.00470190005001 · Cited by 52
Rösler, N., Wichart, I., & Jellinger, K. A. (2001) · Journal of Neural Transmission · doi:10.1007/s007020170091 · Cited by 51
Cerebrospinal Fluid Cytokine Dynamics Differ Between Alzheimer Disease Patients and Elderly Controls
Llano, D. A., Li, J., Waring, J. F., Ellis, T. A., Devanarayan, V., Witte, D. G., & Lenz, R. A. (2011) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31823b2728 · Cited by 49
Romanelli, M. M. C., Licastro, F., Porcellini, E., Dogliotti, G., Galliera, E., Lamont, J. L., Innocenzi, P. J., & Fitzgerald, S. P. (2011) · Biogerontology · doi:10.1007/s10522-011-9335-6 · Cited by 48
Plasma beta amyloid and cytokine profile in women with Alzheimer's disease.
Baranowska-Bik, A., Bik, W., Wolińska‐Witort, E., Martyńska, L., Chmielowska, M., Barcikowska, M., & Baranowska, B. (2008) · PubMed · Cited by 47
Öztürk, C., Özge, A., Yalın, O. Ö., Yılmaz, İ. A., Delialioglu, N., Yıldız, Ç., Tesdelen, B., & Kudiaki, C. (2007) · Behavioural Neurology · doi:10.1155/2007/432190 · Cited by 46
Jurašková, B., Andrýs, C., Holmerová, I., Solichová, D., Hrnčiariková, D., Vaňková, H., Vašátko, T., & Krejsek, J. (2010) · The journal of nutrition health & aging · doi:10.1007/s12603-010-0325-1 · Cited by 44
Diagnostic utility of APOE, soluble CD40, CD40L, and Aβ1–40 levels in plasma in Alzheimer’s disease
Ait‐Ghezala, G., Abdullah, L. I., Volmar, C., Paris, D., Luis, C. A., Quadros, A., Mouzon, B., Mullan, M. A., Keegan, A. P., Parrish, J., et al. (2008) · Cytokine · doi:10.1016/j.cyto.2008.08.013 · Cited by 44
Multiplex Cytokine Concentration Measurement: How Much Do the Medium and Handling Matter?
Parkitny, L., McAuley, J. H., Kelly, P. J., Pietro, F. D., Cameron, B., & Moseley, G. L. (2013) · Mediators of Inflammation · doi:10.1155/2013/890706 · Cited by 43
Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease
Buchhave, P., Janciauskiene, S. M., Zetterberg, H., Blennow, K., Minthon, L., & Hansson, O. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.10.091 · Cited by 41
Novel Systemic Markers for Patients with Alzheimer Disease? – A Pilot Study
Kassner, S. S., Bonaterra, G. A., Kaiser, E., Hildebrandt, W., Metz, J., Schröder, J., & Kinscherf, R. (2008) · Current Alzheimer Research · doi:10.2174/156720508785132253 · Cited by 40
Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples
Kester, M. I., van der Flier, W. M., Visser, A., Blankenstein, M. A., Scheltens, P., & Oudejans, C. B. M. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.731 · Cited by 39
Hernánz, Á., la Fuente, M. D., Navarro, M., & Frank, A. (2007) · NeuroImmunoModulation · doi:10.1159/000110641 · Cited by 39
HARIGAYA, Y., SHOJI, M., NAKAMURA, T., MATSUBARA, E., HOSODA, K., & HIRAI, S. (1995) · Internal Medicine · doi:10.2169/internalmedicine.34.481 · Cited by 38 · cited 1×
“ACT has been extensively studied in AD patients using the methods of immunodiffusion and ELISA [30, 65, 71, 72, 87, 88, 95–100, 132–135].”
MethodMartı́nez, M., Frank, A., & Hernánz, Á. (1993) · Journal of Neuroimmunology · doi:10.1016/0165-5728(93)90197-7 · Cited by 37
Role of Interleukin 6 and Alpha-Globulins in Differentiating Alzheimer and Vascular Dementias
Helmy, A. A., Naseer, M. M. A., Shafie, S. E., & Nada, M. (2011) · Neurodegenerative Diseases · doi:10.1159/000329568 · Cited by 37
Licastro, F., Pedrini, S., Davis, L. J., Caputo, L., Tagliabue, J., Savorani, G., Cucinotta, D., & Annoni, G. (2001) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200101000-00007 · Cited by 30
Serum levels and genetic variation of TGF-β1 are not associated with Alzheimer’s disease
Rodríguez‐Rodríguez, E., Sánchez‐Juan, P., Mateo, I., Llorca, J., Infante, J., García‐Gorostiaga, I., Berciano, J., & Combarros, O. (2007) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2007.00892.x · Cited by 29
Elevation of serum TNF-α levels in mild and moderate Alzheimer patients with daytime sleepiness
Chen, R., Yin, Y., Zhao, Z., Huang, L., Huang, S., Zhuang, J., Wu, H., Peng, H., & Li, P. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2011.12.015 · Cited by 26
Honma, T., Hatta, K., Hitomi, Y., Kambayashi, Y., Hibino, Y., Konoshita, T., & Nakamura, H. (2012) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.3816 · Cited by 24
Matsubara, E., Amari, M., Shoji, M., Harigaya, Y., Yamaguchi, H., Okamoto, K., & Hirai, S. (1989) · PubMed · Cited by 22
Combination of plasma biomarkers and clinical data for the detection of sporadic Alzheimer's disease
Han, Y., Jia, J., Jia, X., Qin, W., & Wang, S. (2012) · Neuroscience Letters · doi:10.1016/j.neulet.2012.03.094 · Cited by 19
Acute phase reactants in Alzheimer's disease
Lawlor, B. A., Swanwick, G., Feighery, C., Walsh, J. B., & Coakley, D. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00426-2 · Cited by 17
Zasada, A. A., Rastawicki, W., Śmietańska, K., Rokosz, N., & Jagielski, M. (2013) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-1823-y · Cited by 15
CSF levels of PSA and PSA–ACT complexes in Alzheimer's disease
Mulder, S. D., Heijst, J. A., Mulder, C., Martens, F., Hack, C. E., Scheltens, P., Blankenstein, M. A., & Veerhuis, R. (2009) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2009.009130 · Cited by 11
Inflammatory Proteins in Plasma and the Risk of Dementia: The Rotterdam Study
Engelhart, M. J., Geerlings, M. I., Meijer, J., Kiliaan, A., Ruitenberg, A., van Swieten, J. C., Stijnen, T., Hofman, A., Witteman, J. C. M., & Breteler, M. M. B. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.668 · Cited by 10
Research works printed but not linked: 1
- Doecke JD et al (2012) Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol 16:1–8
Cited by
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Self-citationNeuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes
Kwon, H. S., & Koh, S.-H. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00221-2 · Cited by 2,595
Immune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134
The Amyloid-β Pathway in Alzheimer’s Disease
Hampel, H., Hardy, J., Blennow, K., Chen, C., Perry, G., Kim, S. H., Villemagne, V. L., Aisen, P., Vendruscolo, M., Iwatsubo, T., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01249-0 · Cited by 1,952
Microglia in Alzheimer's disease
Sarlus, H., & Heneka, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90606 · Cited by 911
Self-citation
Metadata
- Authors
- Brosseron, F., Krauthausen, M., Kummer, M., & Heneka, M. T.
- Affiliations
- German Center for Neurodegenerative Diseases (DE)
- University Hospital Bonn (DE)
- Corresponding author
- Heneka, Michael T.
- Venue
- Molecular Neurobiology
- Published
- 2014-02-25
- Volume
- 50
- Issue
- 2
- Pages
- 534-544
- ISSN
- 0893-7648 (ISSN-L)
- 1559-1182
- PMC
- PMC4182618
- OpenAlex
- W2079873627
- Cited by
- 447
- References
- 143
- Citations by year
- 2026: 14 · 2025: 30 · 2024: 40 · 2023: 58 · 2022: 52 · 2021: 49 · 2020: 49 · 2019: 41 · 2018: 33 · 2017: 29 · 2016: 22 · 2015: 23 · 2014: 7
- FWCI
- 13.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Molecular Neurobiology (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Open Repository and Bibliography (University of Luxembourg) (submittedVersion, other-oa)
- DZNE Pub (submittedVersion, cc-by)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, mild cognitive impairment, cytokines, neuroinflammation, cerebrospinal fluid biomarkers, plasma biomarkers, TNF-α, interleukin-6, neurodegeneration, inflammation-related proteins
- MeSH terms
- Alzheimer Disease, Animals, Body Fluids, Humans, Inflammation, Cytokines, Amyloid beta-Peptides, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.